GLP1R and chronic kidney disease: This document represents the summary of type 2 diabetes management proposed by the American Association of Clinical Endocrinology and the American College of Endocrinology. According to this paper, the risk of hypoglycemia with GLP-1 receptor agonists is low, and they reduce fluctuations in both fasting and postprandial glucose levels. No dose adjustment is required for semaglutide in chronic kidney disease, but monitoring is recommended.